Westfield Capital Management Co. LP Invests $571,000 in argenx SE (NASDAQ:ARGX)

Westfield Capital Management Co. LP acquired a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,053 shares of the company's stock, valued at approximately $571,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. O Shaughnessy Asset Management LLC increased its holdings in shares of argenx by 32.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 1,460 shares of the company's stock worth $575,000 after purchasing an additional 361 shares during the period. Advisors Asset Management Inc. increased its stake in argenx by 79.3% in the first quarter. Advisors Asset Management Inc. now owns 588 shares of the company's stock valued at $232,000 after purchasing an additional 260 shares in the last quarter. Toronto Dominion Bank increased its stake in argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company's stock valued at $119,000 after purchasing an additional 43 shares in the last quarter. Silvercrest Asset Management Group LLC increased its stake in argenx by 14.2% in the first quarter. Silvercrest Asset Management Group LLC now owns 5,184 shares of the company's stock valued at $2,041,000 after purchasing an additional 646 shares in the last quarter. Finally, Dynasty Wealth Management LLC bought a new stake in argenx in the first quarter valued at $213,000. Institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

ARGX has been the subject of several recent research reports. Barclays raised shares of argenx from an "equal weight" rating to an "overweight" rating in a research report on Tuesday, August 6th. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Friday, November 1st. Truist Financial boosted their target price on shares of argenx from $540.00 to $660.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. boosted their target price on shares of argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research report on Monday, November 4th. Finally, Citigroup boosted their target price on shares of argenx from $512.00 to $635.00 and gave the stock a "buy" rating in a research report on Thursday, October 17th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $630.42.

argenx Stock Performance

ARGX traded up $1.50 during midday trading on Tuesday, reaching $607.16. The company had a trading volume of 361,235 shares, compared to its average volume of 310,577. The stock has a market cap of $36.65 billion, a PE ratio of -687.50 and a beta of 0.61. The business has a 50-day moving average price of $559.08 and a two-hundred day moving average price of $491.13. argenx SE has a 12-month low of $327.73 and a 12-month high of $618.40.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the prior year, the company posted ($1.25) EPS. On average, research analysts anticipate that argenx SE will post 2.2 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.